<DOC>
	<DOC>NCT00567502</DOC>
	<brief_summary>This is an observational safety study being conducted in Europe comparing patients taking Xagrid to patients taking other cytoreductive treatments. The plan is to enrol at least 750 subjects taking Xagrid with up to 3000 subjects taking other cytoreductive therapies. The study will collect follow up data for 5 years for each patient enrolled that will focus on collecting data related to pre-defined events (PDEs) and Suspected Serious Adverse Reactions (SSARs).</brief_summary>
	<brief_title>Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRIDÂ® (Anagrelide Hydrochloride) Compared to Other Treatments</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia, Essential</mesh_term>
	<mesh_term>Anagrelide</mesh_term>
	<criteria>High risk ET patients Subjects who can give written informed consent. Subjects taking cytoreductive therapy Contraindications listed by the product being used. Patient cannot be participating in another clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>